Competitive PressureVOXZOGO accounts for nearly 30% of revenues and faces rising competitive pressure from orals with similar efficacy and superior convenience, limiting upside potential.
Product CompetitionBMN 333 may extend the skeletal franchise, but faces the same oral competition risk, even if efficacy is strong.
Stock PerformanceBMRN shares fell nearly 20% on positive competitor TransCon CNP data, underscoring that VOXZOGO competition—not incremental pipeline wins—drives the stock.